As a French-patented innovation, Belight3™ offers a scientifically backed, oral solution for reducing hyperpigmentation and dark spots caused by ageing and UV exposure. Clinically proven to work across all skin types, this nutricosmetic represents a major advancement in skin health. Industry professionals and consumers alike are invited to explore the benefits of Belight3™ at Supply Side West 2024 Booth 417.
A revolutionary approach to hperpigmentation
Belight3™ redefines how hyperpigmentation is addressed by offering an internal, holistic solution that goes beyond traditional topical creams. Formulated with a powerful combination of grape seed and pomace extracts, licorice extract, and vitamin C, Belight3™ works from within to regulate melanin production, targeting the root causes of dark spots, such as UV damage and ageing.
Hyperpigmentation often becomes more visible with age, driven by factors like prolonged sun exposure, hormonal changes, and chronic inflammation. Central to this process is the enzyme tyrosinase, which is the main responsible for melanin production. Belight3™ has been shown to inhibit tyrosinase activity by 85%, with its active ingredients working synergistically to deliver remarkable results. Many users report visible improvements in as little as 11 days.
Scientifically validated for all skin types
Belight3™'s efficacy has been validated through rigorous clinical trials. In a randomised, double-blind, placebo-controlled clinical study on an Asian population, participants experienced significant lightening of dark spots after just 12 weeks of daily supplementation. Using spectrophotometry, the study demonstrated a +76.8% improvement in the Individual Typology Angle (ITA), a key indicator of skin lightness. The trial confirmed both the effectiveness and safety of Belight3™.
A second clinical trial on a Caucasian population further reinforced these findings, showing similar improvements in dark spot reduction and overall skin tone evenness – validated by objective measurements, as well as by clinical evaluation from the dermatologist and consumer feedback. The results of this study are currently pending publication, further establishing Belight3™ as a universal solution for diverse skin types.
Addressing global skin concerns
Between December 2022 and February 2023, an international study led by Ipsos interviewed 48,000 individuals across 34 countries, highlighting the global prevalence of pigmentary disorders. The survey found that 50% of people were concerned with conditions like solar lentigo (sun-related spots), post-inflammatory hyperpigmentation (PIH), melasma, and vitiligo, with women and people of colour more likely to be affected. Of the 22,000 respondents concerned about dark spots, 46% reported a moderate to severe impact on their quality of life.
These findings underscore the market potential for products like Belight3™, which addresses these skin concerns at their core by offering an internal solution to hyperpigmentation. As part of a growing trend in nutricosmetics, Belight3™ offers a more comprehensive, long-lasting alternative to topical treatments.
Real-World Results
Belight3™ has also demonstrated real-world effectiveness. In a real-world study supervised by a dermatologist, 82% of participants expressed satisfaction after two months of use, noting significant improvements in dark spot reduction and skin tone evenness. Participants also reported seeing visible results in an average of just 11 days with 79% disclosing that results were fast.
These strong consumer results position Belight3™ as a game-changer in the global skincare market, tapping into the growing demand for plant-based, science-backed nutricosmetic solutions.
Discover Belight3™ at Supply Side West 2024
Activ'Inside invites industry professionals, media, and consumers to visit Booth 4177 at Supply Side West 2024 to learn more about Belight3™. Attendees can explore the scientific research behind this innovative ingredient, experience its wide-ranging benefits, and connect with the team behind this breakthrough in skincare.
For further details about Belight3™ and its clinical data, visit Booth 4177 or contact Activ'Inside.
